GLSI Greenwich LifeSciences Inc

Price (delayed)

$12.98

Market cap

$190.52M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.57

Enterprise value

$180.02M

?
Relative Growth: Rel. Growth: 3
Relative Strength: Rel. Strength: 22
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 1

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a ...

Highlights
The quick ratio has soared by 90% from the previous quarter and by 5% YoY
The net income has contracted by 23% YoY and by 12% from the previous quarter
GLSI's EPS is down by 16% year-on-year and by 10% since the previous quarter

Key stats

What are the main financial stats of GLSI

GLSI stock price

How has the Greenwich LifeSciences stock price performed over time
Intraday
-1.59%
1 week
-20.47%
1 month
-39.7%
1 year
12.97%
YTD
-38.22%
QTD
-44.67%

Financial performance

How have Greenwich LifeSciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$21.89M
Net income
-$21.76M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 23% YoY and by 12% from the previous quarter
The operating income has declined by 23% year-on-year and by 13% since the previous quarter

Price vs fundamentals

How does GLSI's price correlate with its fundamentals

Growth

What is Greenwich LifeSciences's growth rate over time

Valuation

What is Greenwich LifeSciences stock price valuation
P/E
N/A
P/B
34.12
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
GLSI's EPS is down by 16% year-on-year and by 10% since the previous quarter
GLSI's P/B is 87% lower than its last 4 quarters average of 258.4 and 58% lower than its 5-year quarterly average of 81.5

Efficiency

How efficient is Greenwich LifeSciences business performance
The return on equity has dropped by 74% year-on-year but it has increased by 36% since the previous quarter
The ROA has increased by 25% QoQ but it has decreased by 3.7% YoY

Dividends

What is GLSI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GLSI.

Financial health

How did Greenwich LifeSciences financials performed over time
GLSI's total assets is 101% greater than its total liabilities
The current ratio has soared by 90% from the previous quarter and by 5% YoY
The quick ratio has soared by 90% from the previous quarter and by 5% YoY
The company's debt is 100% lower than its equity

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.